• Reuters

  • SHARE

An experimental treatment from Shionogi & Co. Ltd has shown rapid clearance of the virus that causes COVID-19, according to new data, the Japanese drugmaker said on Sunday.

The pill, S-217622, "demonstrated rapid clearance of the infectious SARS-CoV-2 virus," Shionogi said in a statement, citing Phase-2b results from the Phase II/III clinical trial of the drug.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW

PHOTO GALLERY (CLICK TO ENLARGE)